Medical and Surgical Management of ECLS as Bridge to Recovery and Transplantation for Pulmonary Hypertension: A Large Single Center Experience

• Published in: The Journal of heart and lung transplantation Vol. 38; no. 4; p. S131
• Main Authors: Rosenzweig, E.B., Gannon, W.D., Agerstrand, C.L., Abrams, D., Brodie, D., Bacchetta, M.D.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.04.2019
• ISSN: 1053-2498; 1557-3117
• DOI: 10.1016/j.healun.2019.01.310

Despite advanced targeted medical therapy, patients with pulmonary hypertension (PH) can experience gradual or sudden progression of their symptoms due to an acute insult. Application of extracorporeal life support (ECLS) for advanced PH is evolving. We examined our single-center experience using ECLS as bridge to recovery (BTR), non-transplant surgery (BTNTS), or lung transplantation (BTT) in patients with PH. We conducted a retrospective analysis of all adult patients with non-WHO group 2 PH who received ECLS at New York Presbyterian - Columbia University Medical Center between 2010 and 2018. We describe clinical characteristics and our specialized approach to medical and surgical management in this cohort. There were 98 PH patients in the cohort (54 female; median age 48 years (IQR 32-58)). Thirty-six (36.7%) patients received ECLS with intent to BTR (including 10 BTNTS) and 62 (63.3%) to BTT, including 8 who received ECLS during or immediately after lung transplantation. In the overall cohort, 58 (59.1%) patients received VA-ECLS, including upper body Sport Model (n=13), and upper body Central Sport Model (n=7). Nine (9.2%) patents received VVA-ECLS. Thirty-two (32.7%) patients received VV-ECLS including 4 via a congenital pulmonary-systemic shunt for “VA” physiology. Serum lactate, creatinine, brain natriuretic peptide, and arterial blood gas measures improved after ECLS cannulation. Sixty-eight (70%) patients were liberated from invasive mechanical ventilation while receiving ECLS. Management of PH medications followed an intentional strategy of de-escalation for BTT and ramp down and then ramp up for non-surgical BTR. PH medications including intravenous and inhaled prostanoids, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors were used most often in BTR patients and in WHO group 1 PH BTT patients. Survival to decannulation in this cohort was 85.7%; 30-day survival was 71.4%. ECLS instituted by a specialized, multidisciplinary PH/ECLS team has a growing role in the management of advanced non-WHO group 2 PH as BTR, BTNTS, or to BTT. Careful selection of cannulation configurations, patient-specific optimization of PH medical therapies, and avoidance of endotracheal intubation may be an effective strategy in managing these complex patients.